Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group Arcoxia® | Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
| |
| Group Celebrex® | Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| etorocoxib | Drug | Administered as 30 mg or 60 mg oral film-coated tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Demonstrating Proper Use of Arcoxia® and Celebrex® | Proper use of study medication is defined as administration of medication in terms of indication and dosage according to Market Authorization (MA). Proper use of Arcoxia® is defined as administration of a starting dose of 30 mg daily, not to exceed 60 mg daily during follow-up, for the treatment of symptoms of osteoarthritis. Proper use of Celebrex® is defined as administration of a starting dose of 200 mg daily, not to exceed 400 mg daily during follow-up, for easing symptoms in the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Data to assess proper use were collected through use of a medical questionnaire and patient form. Data pertaining to indication was collected by open-field to allow physicians to precisely indicate the reason for prescription. Recorded indications were then analyzed by two medical experts (an independent expert and a member of the Scientific Community) to assess proper use or misuse. | Up to 12 months |
| Reasons for Misuse of Arcoxia® and Celebrex® | Proper use of study medication is defined as administration of medication in terms of indication and dosage according to MA. Proper use of Arcoxia® is defined as administration of a starting dose of 30 mg daily, not to exceed 60 mg daily during follow-up, for the treatment of symptoms of osteoarthritis. Proper use of Celebrex® is defined as administration of a starting dose of 200 mg daily, not to exceed 400 mg daily during follow-up, for easing symptoms in the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Data to assess proper use were collected through use of a medical questionnaire and patient form. Data pertaining to indication was collected by open-field to allow physicians to precisely indicate the reason for prescription. Recorded indications were then analyzed by two medical experts (an independent expert and a member of the Scientific Community) to assess proper use or misuse. | Up to 12 months |
| Indications for Which Arcoxia® and Celebrex® Were Prescribed | The reasons (indications) for prescribing of Arcoxia® or Celebrex® were collected in open-field forms by the Investigator; category assignment (i.e, re-codification) of verbatim entries was conducted by a group of medical experts under the guidance approved by the MA. This endpoint gives the number of participants treated per indication. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Body Mass Index (BMI) at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Participants' BMI was assessed at study entry by the Investigating Physician. BMI is calculated as the participant's weight in kilograms (kg) divided by height in meters squared. BMI under 18.5 is commonly considered underweight; within the range (18.5 to 25) as normal weight; within the range (25 to 30) as overweight; and over 30 as obese. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Participants spontaneously consulting a general practitioner or rheumatologist and having agreed to take part in this study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
Not provided
621 total participants were screened; 71 participants were excluded for inclusion criteria violation and 3 were excluded for unavailability of informed consent.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Group Arcoxia® | Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
| FG001 | Group Celebrex® | Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Group Arcoxia® | Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
| BG001 | Group Celebrex® |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Demonstrating Proper Use of Arcoxia® and Celebrex® | Proper use of study medication is defined as administration of medication in terms of indication and dosage according to Market Authorization (MA). Proper use of Arcoxia® is defined as administration of a starting dose of 30 mg daily, not to exceed 60 mg daily during follow-up, for the treatment of symptoms of osteoarthritis. Proper use of Celebrex® is defined as administration of a starting dose of 200 mg daily, not to exceed 400 mg daily during follow-up, for easing symptoms in the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Data to assess proper use were collected through use of a medical questionnaire and patient form. Data pertaining to indication was collected by open-field to allow physicians to precisely indicate the reason for prescription. Recorded indications were then analyzed by two medical experts (an independent expert and a member of the Scientific Community) to assess proper use or misuse. | All participants with complete data relative to correct use of the coxib and at least 1 data point relative to misuse of the coxib. | Posted | Number | Participants | Up to 12 months |
Up to 12 months
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. All participants who enrolled in the study were included in the safety reporting.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Group Arcoxia® | Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077613 | Etoricoxib |
| D000068579 | Celecoxib |
| ID | Term |
|---|---|
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
Not provided
Not provided
Not provided
Not provided
Not provided
| celecoxib | Drug | Administered as 100 mg or 200 mg oral hard capsules |
|
|
| At study entry |
| Dosage of Arcoxia® and Celebrex® at Initiation | Dosage at initiation of treatment with Arcoxia® or Celebrex® was identified. MA compliant dosage at initiation corresponds to a (starting) dose of 30 mg daily for Arcoxia® or a (starting) dose of 200 mg daily for Celebrex®. The dose for initiation was calculated by multiplying the number of doses per day with the dose level (total daily dose) as noted in the prescription record. | At study entry |
| Mean Dosage of Arcoxia® and Celebrex® During Treatment | The mean dosage of Arcoxia® and Celebrex® during treatment was determined. For participants who stopped treatment after their initial study visit, the maximum dose recorded at their final study visit was considered when calculating their mean dosage during treatment. | Up to 12 months |
| Number of Participants Requiring Dose Modification of Arcoxia® and Celebrex® | Participants requiring modifications to their Arcoxia® or Celebrex® dose regimens during their on study treatment course were identified. Dose modifications were defined as an increase, decrease followed by increase, decrease, or increase followed by decrease in the participant's daily dose; all categorizations were exclusive. If the maximum dose at discontinuation of treatment was greater than that at initiation, the participant was considered as having had an increase in dose during treatment. Alternatively, if data obtained from a participant's prescription records showed a successive lowering of dosage, the participant was considered as having had a decrease in dose during treatment. Dosages at baseline were included in the dose modification determination for treatment renewal participants. | Up to 12 months |
| Duration of Prescription for Arcoxia® and Celebrex® at Enrollment | The mean duration of prescription at enrollment for participants treated with Arcoxia® and Celebrex® was determined using the participant's record. | Up to 3 months prior to study entry |
| Total Duration of Treatment With Arcoxia® and Celebrex® | The total duration of treatment (DoT) with Arcoxia® or Celebrex® was determined for populations that achieved end-of study and end-of-protocol or that were categorized as lost to follow-up. Participants enumerated as end-of-study had their treatment discontinued during the protocol-specified one year of follow-up. Participants enumerated as end-of-protocol were ongoing treatment at end of the protocol-specified one year of follow-up. Participants categorized as lost to follow-up had no follow-up visit where a determination of discontinuation from treatment could be made. | Up to 12 months |
| Maximum Dosage Prescribed During Treatment With Arcoxia® and Celebrex® | Mean maximum dosage prescribed during follow-up in participants treated with Arcoxia® or Celebrex®. Dosage is expressed as total daily dose. | Up to 12 months |
| Reasons for Discontinuation of Treatment With Arcoxia® and Celebrex® | The individual reasons for discontinuation of treatment with Arcoxia® or Celebrex® were identified over the course of study through either physician selection from a pre-determined list or verbatim entry by the physician with subsequent re-codification by Sponsor. | Up to 12 months |
| Type of Arcoxia® and Celebrex® Use | The type of Arcoxia® or Celebrex® use during the study was classified as continuous (without interruption >7 days) or intermittent (with interruption >7 days) by the Investigating Physician at time of treatment discontinuation. | Up to 12 months |
| Type of Arcoxia® and Celebrex® Use According to Duration of Treatment | Use of selective cyclooxygenase-2 (COX-2) inhibitors (Arcoxia® and Celebrex®) as assessed by the Investigating Physician at time of treatment discontinuation was correlated to the overall duration of treatment experienced by the participant (i.e., intermittent or continuous selective COX-2 inhibitor use vs. total participant time on treatment). Type of use was classified as continuous (without interruption >7 days) or intermittent (with interruption >7 days). Four successive treatment intervals were assessed in this endpoint: 1) Up to thirty days of treatment 2) From one to three months of treatment 3) From three months to one year of treatment and 4) More than one year of treatment. | Up to 12 months |
| At study entry (baseline) |
| Mean Systolic and Diastolic Blood Pressure (BP) at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were assessed at study entry by the Investigating Physician. Definition of controlled BP: SBP <140 mmHg and DBP <90 mmHg. Definition of uncontrolled BP: SBP ≥140 mmHg and/or DBP ≥90 mmHg. | At study entry (baseline) |
| Blood Pressure at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Participants' BP (SBP/DBP) was assessed at study entry by the Investigating Physician. Definition of controlled BP: SBP <140 mmHg and DBP <90 mmHg. Definition of uncontrolled BP: SBP ≥140 mmHg and/or DBP ≥90 mmHg. | At study entry (baseline) |
| Medical History of Participants Treated With Arcoxia® and Celebrex® | Relevant medical history of participants treated with Arcoxia® or Celebrex® was recorded by the Investigating Physician. | At study entry |
| Co-morbidities in Participants Treated With Arcoxia® and Celebrex® | Associated co-morbidities at study entry (baseline) in participants treated with Arcoxia® or Celebrex® were recorded by the Investigating Physician. CHF/IHD/PAD = Congestive heart failure/Ischemic heart disease/Peripheral artery disease | At study entry |
| Significant Past Treatments Prior to Initiating Treatment With Arcoxia® or Celebrex® | 'Significant' treatments that preceded the use of selective COX-2 inhibitors (Arcoxia® or Celebrex®) were identified using a closed-ended (yes/ no/ do not know) questionnaire. Significant is defined as associated with a chronic disease or having a potential link with participant's current use of a selective COX-2 inhibitors (Arcoxia® or Celebrex®). ARBs = Angiotensin 2 receptor blockers. ACEIs = Angiotensin-converting enzyme inhibitors. SSRIs = Selective serotonin reuptake Inhibitors. PAIs = Platelet aggregation inhibitors. | At study entry |
| Medications Co-Prescribed at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Concomitant medications prescribed to participants treated with Arcoxia® and Celebrex® were collected via the physician prescription note at time of participant's study entry. NSAIDS = Non-steroidal anti-inflammatory agents. | At study entry |
| Medications Co-Prescribed Over the Course of Follow-up With Arcoxia® and Celebrex® | Concomitant medications prescribed during the course of follow-up to participants treated with Arcoxia® and Celebrex® were extracted from participants' medical records. NSAIDS = Non-steroidal anti-inflammatory agents. | Up to 12 months |
| Number of Participants Treated With Other Agents Prior to Initiation of Arcoxia® and Celebrex® | Other prescribed agents for the same study indication within 3 months preceding the decision to initiate treatment with selective COX-2 inhibitors (Arcoxia® or Celebrex®) were determined using the participant's medical record. NSAIDS = Non-steroidal inflammatory agents. | Up to 3 months prior to study entry |
| Number of Participants Switching to Another Treatment With the Same Reason for Prescription | Participants who switched to another NSAID or other therapy for the same reason for prescription upon discontinuation of treatment with Arcoxia® or Celebrex® were determined. | Up to 12 months |
| Number of Participants With Contraindications for Use of Arcoxia® | Participants noted with contraindications for use of Arcoxia® according to the MA during initiation of treatment are described. CHF = congestive heart failure. HA = hepatic impairment. IBD = inflammatory bowel disease. IHD = ischemic heart disease. PAD = peripheral artery disease. | At study entry |
| Number of Participants Who Experienced at Least One Adverse Event | An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. | Up to 12 months |
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | Discontinuation/withdrawal of study treatment due to an adverse event was performed at the discretion of the investigator or the Sponsor for safety concerns. An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. | Up to 12 months |
| Lack of Efficacy |
|
| Intolerance |
|
| Improved symptoms |
|
| Surgical intervention |
|
| Withdrawal by Subject |
|
| Physician Decision |
|
| Death unrelated to coxibs |
|
| Other disease detected |
|
| Unknown reason |
|
| Rheumatologist new evaluation |
|
| Missing data |
|
| Lost to Follow-up |
|
Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| ID | Title | Description |
|---|
| OG000 | Group Arcoxia® | Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
| OG001 | Group Celebrex® | Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. |
|
|
| Primary | Reasons for Misuse of Arcoxia® and Celebrex® | Proper use of study medication is defined as administration of medication in terms of indication and dosage according to MA. Proper use of Arcoxia® is defined as administration of a starting dose of 30 mg daily, not to exceed 60 mg daily during follow-up, for the treatment of symptoms of osteoarthritis. Proper use of Celebrex® is defined as administration of a starting dose of 200 mg daily, not to exceed 400 mg daily during follow-up, for easing symptoms in the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Data to assess proper use were collected through use of a medical questionnaire and patient form. Data pertaining to indication was collected by open-field to allow physicians to precisely indicate the reason for prescription. Recorded indications were then analyzed by two medical experts (an independent expert and a member of the Scientific Community) to assess proper use or misuse. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (misuse) | Posted | Number | Participants | Up to 12 months |
|
|
|
| Primary | Indications for Which Arcoxia® and Celebrex® Were Prescribed | The reasons (indications) for prescribing of Arcoxia® or Celebrex® were collected in open-field forms by the Investigator; category assignment (i.e, re-codification) of verbatim entries was conducted by a group of medical experts under the guidance approved by the MA. This endpoint gives the number of participants treated per indication. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (indication) | Posted | Number | Participants | At study entry |
|
|
|
| Primary | Dosage of Arcoxia® and Celebrex® at Initiation | Dosage at initiation of treatment with Arcoxia® or Celebrex® was identified. MA compliant dosage at initiation corresponds to a (starting) dose of 30 mg daily for Arcoxia® or a (starting) dose of 200 mg daily for Celebrex®. The dose for initiation was calculated by multiplying the number of doses per day with the dose level (total daily dose) as noted in the prescription record. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (dosage at initiation) | Posted | Number | Participants | At study entry |
|
|
|
| Primary | Mean Dosage of Arcoxia® and Celebrex® During Treatment | The mean dosage of Arcoxia® and Celebrex® during treatment was determined. For participants who stopped treatment after their initial study visit, the maximum dose recorded at their final study visit was considered when calculating their mean dosage during treatment. | All participants who discontinued treatment during follow-up or were still on treatment after one year of follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Mean | Standard Deviation | mg/day | Up to 12 months |
|
|
|
| Primary | Number of Participants Requiring Dose Modification of Arcoxia® and Celebrex® | Participants requiring modifications to their Arcoxia® or Celebrex® dose regimens during their on study treatment course were identified. Dose modifications were defined as an increase, decrease followed by increase, decrease, or increase followed by decrease in the participant's daily dose; all categorizations were exclusive. If the maximum dose at discontinuation of treatment was greater than that at initiation, the participant was considered as having had an increase in dose during treatment. Alternatively, if data obtained from a participant's prescription records showed a successive lowering of dosage, the participant was considered as having had a decrease in dose during treatment. Dosages at baseline were included in the dose modification determination for treatment renewal participants. | All participants who discontinued treatment during follow-up or were still on treatment after one year of follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Number | Participants | Up to 12 months |
|
|
|
| Primary | Duration of Prescription for Arcoxia® and Celebrex® at Enrollment | The mean duration of prescription at enrollment for participants treated with Arcoxia® and Celebrex® was determined using the participant's record. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (duration of prescription) | Posted | Mean | Standard Deviation | Days | Up to 3 months prior to study entry |
|
|
|
|
| Primary | Total Duration of Treatment With Arcoxia® and Celebrex® | The total duration of treatment (DoT) with Arcoxia® or Celebrex® was determined for populations that achieved end-of study and end-of-protocol or that were categorized as lost to follow-up. Participants enumerated as end-of-study had their treatment discontinued during the protocol-specified one year of follow-up. Participants enumerated as end-of-protocol were ongoing treatment at end of the protocol-specified one year of follow-up. Participants categorized as lost to follow-up had no follow-up visit where a determination of discontinuation from treatment could be made. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (duration of prescription) | Posted | Mean | Standard Deviation | Days | Up to 12 months |
|
|
|
| Primary | Maximum Dosage Prescribed During Treatment With Arcoxia® and Celebrex® | Mean maximum dosage prescribed during follow-up in participants treated with Arcoxia® or Celebrex®. Dosage is expressed as total daily dose. | All participants who discontinued treatment during follow-up or were still on treatment after one year of follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Mean | Standard Deviation | mg/day | Up to 12 months |
|
|
|
| Primary | Reasons for Discontinuation of Treatment With Arcoxia® and Celebrex® | The individual reasons for discontinuation of treatment with Arcoxia® or Celebrex® were identified over the course of study through either physician selection from a pre-determined list or verbatim entry by the physician with subsequent re-codification by Sponsor. | All participants who discontinued treatment during follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Number | Participants | Up to 12 months |
|
|
|
| Primary | Type of Arcoxia® and Celebrex® Use | The type of Arcoxia® or Celebrex® use during the study was classified as continuous (without interruption >7 days) or intermittent (with interruption >7 days) by the Investigating Physician at time of treatment discontinuation. | All participants who discontinued treatment during follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Number | Participants | Up to 12 months |
|
|
|
| Primary | Type of Arcoxia® and Celebrex® Use According to Duration of Treatment | Use of selective cyclooxygenase-2 (COX-2) inhibitors (Arcoxia® and Celebrex®) as assessed by the Investigating Physician at time of treatment discontinuation was correlated to the overall duration of treatment experienced by the participant (i.e., intermittent or continuous selective COX-2 inhibitor use vs. total participant time on treatment). Type of use was classified as continuous (without interruption >7 days) or intermittent (with interruption >7 days). Four successive treatment intervals were assessed in this endpoint: 1) Up to thirty days of treatment 2) From one to three months of treatment 3) From three months to one year of treatment and 4) More than one year of treatment. | All participants who discontinued treatment during follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Number | Participants | Up to 12 months |
|
|
|
|
| Secondary | Mean Body Mass Index (BMI) at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Participants' BMI was assessed at study entry by the Investigating Physician. BMI is calculated as the participant's weight in kilograms (kg) divided by height in meters squared. BMI under 18.5 is commonly considered underweight; within the range (18.5 to 25) as normal weight; within the range (25 to 30) as overweight; and over 30 as obese. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (BMI) | Posted | Mean | Standard Deviation | kg/m^2 | At study entry (baseline) |
|
|
|
| Secondary | Mean Systolic and Diastolic Blood Pressure (BP) at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were assessed at study entry by the Investigating Physician. Definition of controlled BP: SBP <140 mmHg and DBP <90 mmHg. Definition of uncontrolled BP: SBP ≥140 mmHg and/or DBP ≥90 mmHg. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (SBP and DBP) | Posted | Mean | Standard Deviation | mmHG | At study entry (baseline) |
|
|
|
| Secondary | Blood Pressure at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Participants' BP (SBP/DBP) was assessed at study entry by the Investigating Physician. Definition of controlled BP: SBP <140 mmHg and DBP <90 mmHg. Definition of uncontrolled BP: SBP ≥140 mmHg and/or DBP ≥90 mmHg. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (BP) | Posted | Number | Participants | At study entry (baseline) |
|
|
|
|
| Secondary | Medical History of Participants Treated With Arcoxia® and Celebrex® | Relevant medical history of participants treated with Arcoxia® or Celebrex® was recorded by the Investigating Physician. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (medical history) | Posted | Number | Participants | At study entry |
|
|
|
|
| Secondary | Co-morbidities in Participants Treated With Arcoxia® and Celebrex® | Associated co-morbidities at study entry (baseline) in participants treated with Arcoxia® or Celebrex® were recorded by the Investigating Physician. CHF/IHD/PAD = Congestive heart failure/Ischemic heart disease/Peripheral artery disease | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (co-morbidities) | Posted | Number | Participants | At study entry |
|
|
|
| Secondary | Significant Past Treatments Prior to Initiating Treatment With Arcoxia® or Celebrex® | 'Significant' treatments that preceded the use of selective COX-2 inhibitors (Arcoxia® or Celebrex®) were identified using a closed-ended (yes/ no/ do not know) questionnaire. Significant is defined as associated with a chronic disease or having a potential link with participant's current use of a selective COX-2 inhibitors (Arcoxia® or Celebrex®). ARBs = Angiotensin 2 receptor blockers. ACEIs = Angiotensin-converting enzyme inhibitors. SSRIs = Selective serotonin reuptake Inhibitors. PAIs = Platelet aggregation inhibitors. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (past treatments) | Posted | Number | Participants | At study entry |
|
|
|
|
| Secondary | Medications Co-Prescribed at Study Entry in Participants Treated With Arcoxia® and Celebrex® | Concomitant medications prescribed to participants treated with Arcoxia® and Celebrex® were collected via the physician prescription note at time of participant's study entry. NSAIDS = Non-steroidal anti-inflammatory agents. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (co-prescriptions at entry) | Posted | Number | Participants | At study entry |
|
|
|
| Secondary | Medications Co-Prescribed Over the Course of Follow-up With Arcoxia® and Celebrex® | Concomitant medications prescribed during the course of follow-up to participants treated with Arcoxia® and Celebrex® were extracted from participants' medical records. NSAIDS = Non-steroidal anti-inflammatory agents. | All participants in compliance with study inclusion criteria with at least one follow-up visit (with an available prescription file) other than the end-of-study visit were used for analysis of the endpoint | Posted | Number | Participants | Up to 12 months |
|
|
|
| Secondary | Number of Participants Treated With Other Agents Prior to Initiation of Arcoxia® and Celebrex® | Other prescribed agents for the same study indication within 3 months preceding the decision to initiate treatment with selective COX-2 inhibitors (Arcoxia® or Celebrex®) were determined using the participant's medical record. NSAIDS = Non-steroidal inflammatory agents. | The per protocol analysis population consisting of all participants in compliance with study inclusion criteria with data of sufficient quality for analysis of the endpoint (other prior agents) | Posted | Number | Participants | Up to 3 months prior to study entry |
|
|
|
|
| Secondary | Number of Participants Switching to Another Treatment With the Same Reason for Prescription | Participants who switched to another NSAID or other therapy for the same reason for prescription upon discontinuation of treatment with Arcoxia® or Celebrex® were determined. | All participants who discontinued treatment during follow-up under protocol; participants who were lost to follow-up were excluded from this analysis. | Posted | Number | Participants | Up to 12 months |
|
|
|
| Secondary | Number of Participants With Contraindications for Use of Arcoxia® | Participants noted with contraindications for use of Arcoxia® according to the MA during initiation of treatment are described. CHF = congestive heart failure. HA = hepatic impairment. IBD = inflammatory bowel disease. IHD = ischemic heart disease. PAD = peripheral artery disease. | The safety population consisting of all participants who enrolled in the study with data of sufficient quality for analysis of the endpoint (contraindications) | Posted | Number | Participants | At study entry |
|
|
|
| Secondary | Number of Participants Who Experienced at Least One Adverse Event | An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. | The safety population consisting of all participants who enrolled in the study | Posted | Number | Participants | Up to 12 months |
|
|
|
|
| Secondary | Number of Participants Who Discontinued Study Drug Due to an Adverse Event | Discontinuation/withdrawal of study treatment due to an adverse event was performed at the discretion of the investigator or the Sponsor for safety concerns. An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. | The safety population consisting of all participants who enrolled in the study | Posted | Number | Participants | Up to 12 months |
|
|
|
| 0 |
| 268 |
| 0 |
| 268 |
| EG001 | Group Celebrex® | Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use. | 0 | 279 | 0 | 279 |
Not provided
Not provided
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000096926 | Benzenesulfonamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011720 | Pyrazoles |
| D001393 | Azoles |
| Non-MA-Compliant Starting Dose and Indication |
|
| Non-MA-Compliant Indication & Dose (Starting &Max) |
|
| Inflammatory rheumatism |
|
| Neuralgia |
|
| Non-joint rheumatism |
|
| Unclassified arthropathy |
|
| Missing data |
|
| > 60 mg; <100 mg |
|
| 100 mg |
|
| >100 mg; < 200 mg |
|
| 200 mg |
|
| 400 mg |
|
| > 400 mg |
|
| Dose decrease followed by increase |
|
| Dose decrease |
|
| Dose increase followed by decrease |
|
| p-student |
| <0.001 |
| Superiority or Other (legacy) |
| DoT - Lost to follow-up participants (n=5,4) |
|
| Lack of efficacy |
|
| Intolerance |
|
| Improved symptoms |
|
| Surgical intervention |
|
| Participant decision |
|
| Physician decision |
|
| Death unrelated to coxibs |
|
| Other disease detected |
|
| Other - unknown reason |
|
| Rheumatologist new evaluation |
|
| Missing data |
|
| Continuous |
|
| Intermittent |
|
| Continuous |
|
| DBP |
|
| <120/80 mmHg |
|
| 120 mmHg ≤SBP<140 mmHg and/or 80 mmHg ≤DBP<90 mmHg |
|
| 140 mmHg ≤SBP<180 mmHg and/or 90 mmHg≤DBP<100 mmHg |
|
| SBP≥180 mmHg and/or DBP≥110 mmHg |
|
| Chi-squared |
| 0.0049 |
| Superiority or Other (legacy) |
| Group comparison (Celebrex® [Initiation] vs Celebrex® [Renewal]) for controlled BP (SBP <140 mmHg and DBP <90 mmHg) at study entry | Chi-squared | 0.618 | Superiority or Other (legacy) |
| Acute rhinitis (n=145,115,115,157,260,272) |
|
| Bronchospam (n=145,117,115,158,262,273) |
|
| Urticaria (n=146,116,115,156,262,271) |
|
| Peptic ulcer/bleeding (n=146,118,117,158,264,275) |
|
| Angioedema (n=145,117,114,157,262,271) |
|
| Nasal polyps (n=146,116,114,158,262,272) |
|
| Chi-squared |
| 0.175 |
| Superiority or Other (legacy) |
| Hyperlipidemia |
|
| Diabetes |
|
| Hepatic insufficiency |
|
| Inflammatory bowel disease |
|
| CHF/IHD/PAD |
|
| Active peptic ulceration/ GI bleeding |
|
| Missing data |
|
| Proton-pump inhibitors (n=146,115,116,156,261,272) |
|
| Hypolipidemic agents (n=146,116,117,156,262,273) |
|
| ARBs (n=144,115,116,155,259,271) |
|
| Diuretics (N=146,117,117,156,263,273) |
|
| ACEIs (n=145,116,117,157,261,274) |
|
| SSRIs (n=146,116,117,158,262,275) |
|
| Anti-diabetic agents (n=146,115,117,158,261,275) |
|
| Histamine H2 blockers (n=146,117,117,156,263,273) |
|
| PAIs (n=146,118,117,158,264,275) |
|
| Oral anticoagulants (n=146,118,117,158,264,275) |
|
| Alpha-blockers (n=146,116,117,157,262,274) |
|
| Chi-squared |
| 0.007 |
| Superiority or Other (legacy) |
| Group comparison (Arcoxia® vs Celebrex®) for significant past treatments | Chi-squared | 0.955 | Superiority or Other (legacy) |
| At least one treatment |
|
| Analgesics |
|
| Cardiovascular agents |
|
| Digestive system agents |
|
| Nervous system agents |
|
| NSAIDS |
|
| Rheumatologic agents |
|
| Metabolic system agents |
|
| Respiratory system agents |
|
| Hormonal agents |
|
| Hematologic agents |
|
| Urinary-genital system agents |
|
| Dermatological agents |
|
| Anti-infectious agents |
|
| Other not-classified |
|
| Analgesics |
|
| Cardiovascular agents |
|
| Digestive system agents |
|
| Nervous system agents |
|
| Respiratory system agents |
|
| Metabolic system agents |
|
| Rheumatologic agents |
|
| NSAIDS |
|
| Anti-infectious agents |
|
| Hormonal agents |
|
| Dermatological agents |
|
| Hematologic agents |
|
| Urinary-genital system agents |
|
| Other |
|
| Paracetamol (n=146,118,117,158,264,275) |
|
| NSAIDS (n=146,118,117,158,264,275) |
|
| Analgesics (n=146,118,117,158,264,275) |
|
| Corticosteroids (n=140,107,111,152,247,263) |
|
| Analgesics |
|
| Other (TNF-alpha inhibitors, corticosteroids) |
|
|
| Two total contraindications (n=36,34,70) |
|
| History of acute rhinitis (n=145,115,260) |
|
| Creatinine clearance <30 ml/min (n=125,108,233) |
|
| History of bronchospasm (n=145,117,262) |
|
| History of urticaria (n=146,116,262) |
|
| Presence of IBD (n=146,118,264) |
|
| Presence of CHF (n=146,118,264) |
|
| Presence of IHD and/or PAD (n=142,118,260) |
|
| History of allergic reaction (n=145,118,263) |
|
| History of nasal polyps (n=146,116,262) |
|
| Blood pressure not controlled (n=146,118,264) |
|
| History of angioedema (n=145,117,262) |
|
| Patients with severe HA (n=146,118,264) |
|
| <16 years of age (n=149,119,268) |
|
| Pregnancy or lactation (n=92,73,165) |
|